Target family: Catecholamine turnover (type: enzyme)
Target: Monoamine oxidase B

Ligand: bifemelane (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Japan only
Primary target: no
Median affinity: 4.340000152587891 pKi
Reference (Journal): 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase.
Published in: J Neurochem

Ligand: lazabemide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.079999923706055 pKi
Reference (Journal): Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
Published in: Adv Neurol

Ligand: lazabemide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.079999923706055 pKi
Reference (Journal): Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
Published in: Bioorg Med Chem Lett

Ligand: linezolid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2000), UK (2001)
Primary target: no
Median affinity: 8.319999694824219 pIC50
Reference (Journal): Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
Published in: Eur J Med Chem

Ligand: linezolid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2000), UK (2001)
Primary target: no
Median affinity: 5.679999828338623 pIC50
Reference (Journal): Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives.
Published in: Eur J Med Chem

Ligand: moclobemide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity: 5.96999979019165 pKi
Reference (Journal): Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
Published in: Bioorg Med Chem Lett

Ligand: mofegiline (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.4399995803833 pIC50
Reference (Journal): MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
Published in: J Neural Transm Park Dis Dement Sect

Ligand: pargyline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity: 5.739999771118164 pIC50
Reference (Journal): The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
Published in: Biochem Pharmacol

Ligand: phenelzine (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: yes
Approval source: FDA (1961)
Primary target: yes
Median affinity: 7.820000171661377 pKi
Reference (Journal): Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B.
Published in: Biochemistry

Ligand: rasagiline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2005), FDA (2006)
Primary target: yes
Median affinity: 7.849999904632568 pIC50
Reference (Journal): Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Published in: Br J Pharmacol

Ligand: safinamide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2015), FDA (2017)
Primary target: yes
Median affinity: 6.349999904632568 pKi
Reference (Journal): Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.
Published in: J Med Chem

Ligand: safinamide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2015), FDA (2017)
Primary target: yes
Median affinity: 8.109999656677246 pIC50
Reference (Journal): 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Published in: Bioorg Med Chem

Ligand: selegiline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
Published in: J Med Chem

Ligand: selegiline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.
Published in: Bioorg Med Chem Lett

Ligand: tranylcypromine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1961)
Primary target: yes
Median affinity: 4.71999979019165 pIC50
Reference (Journal): Fluorinated phenylcyclopropylamines. Part 3: Inhibition of monoamine oxidase A and B.
Published in: Bioorg Med Chem